Search - tctmd.com

Displaying 181 - 200 of 327

Sort: Relevancy | Date

Presentation TCT 2017

Flash Debate #2: Is Shortening D2B Time Still Important in Primary PCI? No - Other Quality Metrics Are More Important!

Presenter: Jun-Jack Cheng, Kenneth Chin, Sreenivas Arramraju Kumar

October 29, 2017

Presentation TCT 2017

Flash Debate #2: Is Shortening D2B Time Still Important in Primary PCI? Yes- D2B Time Is an Index of Quality Care for STEMI!

Presenter: Jun-Jack Cheng, Kenneth Chin, Wei-Chun Huang

October 29, 2017

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Industry News TCT 2016

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

November 02, 2016

News Industry News TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

November 02, 2016

News Conference News TCT 2016

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Todd Neale

November 02, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: PARTNER I 5-YEAR Echo and PARTNER II Quality of Life

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Ganesh Manoharan

November 01, 2016

News Industry News TCT 2016

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

November 01, 2016

News Industry News TCT 2016

Long-Term Study Results Show that PFO Closure is More Effective Than Medical Management in Preventing Recurrent Stroke

November 01, 2016

Presentation TCT 2016

How Much Radiation Do I Use Compared to Others? Review of Reference Levels and QA Policies

Presenter: Stephen Balter, Donald L. Miller

November 01, 2016

Presentation TCT 2016

Hot: Is High Dose Due to Operator Preferences or Patient Characteristics?

Presenter: Stephen Balter, Sanjog Kalra

November 01, 2016

Presentation TCT 2016

Ethics of Irradiating Patients and Staff

Presenter: Stephen Balter, Charles E. Chambers

November 01, 2016

News Industry News TCT 2016

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

News Industry News TCT 2016

Dedicated Stent Study Conducted in Women and Minority Assesses Risks of Adverse Cardiovascular Events Following Coronary Stent Procedures

November 01, 2016

Presentation TCT 2016

Strengths and Limitations of Post-Approval Registries as Vehicles to Track Safety and Inform Device Label Expansion

Presenter: Owen Faris, Mitchell W. Krucoff, David R. Holmes Jr.

October 31, 2016

Presentation TCT 2016

Risk Scores: Development, Validation, Utility, and Limitations (With Case Studies: Framingham, TIMI/GRACE, CHADS/HASBLED, DAPT, and Others)

Presenter: Scott Berry, Stuart J. Pocock, Ajay J. Kirtane

October 30, 2016

Presentation TCT 2016

Mediation Analysis: A Method to Assign Attributable Risk

Presenter: Scott Berry, Stuart J. Pocock, Bjorn Redfors

October 30, 2016

Presentation TCT 2016

Surrogate Endpoints: Construction, Validation, and Trustiness

Presenter: Scott Berry, Stuart J. Pocock, William S. Weintraub

October 30, 2016

Advertisement

Flash Debate #2: Is Shortening D2B Time Still Important in Primary PCI? No - Other Quality Metrics Are More Important!

Flash Debate #2: Is Shortening D2B Time Still Important in Primary PCI? Yes- D2B Time Is an Index of Quality Care for STEMI!

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Highlights (and my Interpretations) From: PARTNER I 5-YEAR Echo and PARTNER II Quality of Life

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

Long-Term Study Results Show that PFO Closure is More Effective Than Medical Management in Preventing Recurrent Stroke

How Much Radiation Do I Use Compared to Others? Review of Reference Levels and QA Policies

Hot: Is High Dose Due to Operator Preferences or Patient Characteristics?

Ethics of Irradiating Patients and Staff

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Dedicated Stent Study Conducted in Women and Minority Assesses Risks of Adverse Cardiovascular Events Following Coronary Stent Procedures

Strengths and Limitations of Post-Approval Registries as Vehicles to Track Safety and Inform Device Label Expansion

Risk Scores: Development, Validation, Utility, and Limitations (With Case Studies: Framingham, TIMI/GRACE, CHADS/HASBLED, DAPT, and Others)

Mediation Analysis: A Method to Assign Attributable Risk

Surrogate Endpoints: Construction, Validation, and Trustiness

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content